A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.

@article{Patnaik2016AFP,
  title={A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.},
  author={Amita Patnaik and Paul J Haluska and Anthony William Tolcher and Charles E Erlichman and Kyriakos P. Papadopoulos and Janet L Lensing and Muralidhar Beeram and J. Molina and Drew Warren Rasco and Rebecca R Arcos and Claudia Sue Kelly and Sameera R. Wijayawardana and Xuekui Zhang and Louis F. Stancato and Robert K. Bell and Peipei Shi and Palaniappan Kulanthaivel and Celine Pitou and Lynette B Mulle and Daphne L. Farrington and Edward Michael Chan and Matthew P. Goetz},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2016},
  volume={22 5},
  pages={1095-102}
}
PURPOSE p38 MAPK regulates the production of cytokines in the tumor microenvironment and enables cancer cells to survive despite oncogenic stress, radiotherapy, chemotherapy, and targeted therapies. Ralimetinib (LY2228820 dimesylate) is a selective small-molecule inhibitor of p38 MAPK. This phase I study aimed to evaluate the safety and tolerability of ralimetinib, as a single agent and in combination with tamoxifen, when administered orally to patients with advanced cancer. EXPERIMENTAL… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS
9 Citations
16 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Similar Papers

Loading similar papers…